[HTML][HTML] Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7
K Li, ZY Peng, R Wang, X Li, N Du, DP Liu, J Zhang… - Molecular Cancer, 2023 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) that specifically target mutational
points in the EGFR gene have significantly reduced suffering and provided greater relief to …
points in the EGFR gene have significantly reduced suffering and provided greater relief to …
Neoantigen quality, not quantity
N McGranahan, C Swanton - Science Translational Medicine, 2019 - science.org
Neoantigen quality, not quantity | Science Translational Medicine news careers commentary
Journals Science Science brought to you byGoogle Indexer Log in science science advances …
Journals Science Science brought to you byGoogle Indexer Log in science science advances …
Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib
Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates
signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full …
signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full …
YES1: A novel therapeutic target and biomarker in cancer
YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases (SFK) and
controls multiple cancer signaling pathways. YES1 is amplified and overexpressed in many …
controls multiple cancer signaling pathways. YES1 is amplified and overexpressed in many …
[PDF][PDF] Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
R Roskoski Jr - Pharmacol. Res, 2023 - researchgate.net
Owing to genetic alterations and overexpression, the dysregulation of protein kinases plays
a significant role in the pathogenesis of many autoimmune and neoplastic disorders and …
a significant role in the pathogenesis of many autoimmune and neoplastic disorders and …
Pharmacological modulation of the crosstalk between aberrant Janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer
AHM Mustafa, OH Krämer - Pharmacological Reviews, 2023 - ASPET
Hyperactivated Janus kinase (JAK) signaling is an appreciated drug target in human
cancers. Numerous mutant JAK molecules as well as inherent and acquired drug resistance …
cancers. Numerous mutant JAK molecules as well as inherent and acquired drug resistance …
Acquired resistance mechanisms to osimertinib: the constant battle
Z Zalaquett, MCR Hachem, Y Kassis, S Hachem… - Cancer Treatment …, 2023 - Elsevier
Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver
mutations have now changed the course of lung cancer treatment with the emergence of …
mutations have now changed the course of lung cancer treatment with the emergence of …
Deubiquitinating enzymes: Promising targets for drug resistance
F Ge, Y Li, T Yuan, Y Wu, Q He, B Yang, H Zhu - Drug Discovery Today, 2022 - Elsevier
Highlights•Drug resistance towards chemotherapy and molecularly targeted therapies
remains a great challenge in cancer treatments.•Deubiquitinating enzymes (DUBs) regulate …
remains a great challenge in cancer treatments.•Deubiquitinating enzymes (DUBs) regulate …
[HTML][HTML] Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation
Y Shi, S Zhang, X Hu, J Feng, Z Ma, J Zhou… - Journal of Thoracic …, 2020 - Elsevier
Introduction Alflutinib (AST2818) is a newly developed third-generation EGFR tyrosine
kinase inhibitor selective for EGFR-sensitizing and T790M-resistant mutations. We assessed …
kinase inhibitor selective for EGFR-sensitizing and T790M-resistant mutations. We assessed …
[HTML][HTML] Structure–activity relationship studies based on quinazoline derivatives as EGFR kinase inhibitors (2017–present)
The epidermal growth factor receptor (EGFR) plays a critical role in the tumorigenesis of
various forms of cancer. Targeting the mutant forms of EGFR has been identified as an …
various forms of cancer. Targeting the mutant forms of EGFR has been identified as an …